AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31465154 — intervention group
Group type: COMPARATOR
Intervention: Complior
Number of subjects: 211
Study 26890930 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning discriminative subspaces using principal component analysis and random contrasts for image saliency analysis.
Number of subjects: 0
Study 25356603 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg bid
Number of subjects: 0
Study 25356603 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib 100 mg qd
Number of subjects: 0
Study 23769755 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L polyethylene glycol+ascorbate
Number of subjects: 400
Study 23769755 — intervention group
Group type: COMPARATOR
Intervention: 4L polyethylene glycol solution
Number of subjects: 400
Study 21665011 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Disorders (FD) diagnosed by psychiatric research interview
Number of subjects: 1785
Study 21665011 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically Unexplained Symptoms (MUS) diagnosed by GP
Number of subjects: 1785
Study 21665011 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 4 symptoms
Number of subjects: 1785
Study 21665011 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Disorders (FD)
Number of subjects: 1785
Study 21665011 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically Unexplained Symptoms (MUS)
Number of subjects: 1785
Study 21665011 — intervention group
Group type: COMPARATOR
Intervention: Neither FD nor MUS
Number of subjects: 1785
Study 18637100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical estriol
Number of subjects: 36
Study 18637100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 17924131 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/m3 epsilon-caprolactam vapours
Number of subjects: 20
Study 17924131 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/m3 epsilon-caprolactam vapours
Number of subjects: 20
Study 17924131 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/m3 epsilon-caprolactam vapours
Number of subjects: 20
Study 17924131 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/m3 epsilon-caprolactam vapours (control)
Number of subjects: 20
Study 15361119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low socioeconomic class children
Number of subjects: 176
Study 15361119 — intervention group
Group type: COMPARATOR
Intervention: High socioeconomic class children
Number of subjects: 176
Study 15361119 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged <3 years
Number of subjects: 176
Study 15361119 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 3-6 years
Number of subjects: 176
Study 15361119 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 7-10 years
Number of subjects: 176
Study 15361119 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 176
Study 15361119 — intervention group
Group type: COMPARATOR
Intervention: Females
Number of subjects: 176
Study 11595778 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (17beta estradiol plus cyclic norethisterone acetate)
Number of subjects: 16
Study 11595778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9876789 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural PCA with pethidine
Number of subjects: 25
Study 9876789 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA with pethidine
Number of subjects: 25
Study 8023265 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus amikacin
Number of subjects: 67
Study 8023265 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus aztreonam
Number of subjects: 67
Study 2730824 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 50
Study 2730824 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 50
Study 4140268 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine injection
Number of subjects: 31
Study 4140268 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective vagotomy
Number of subjects: 31
Study 4140268 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy
Number of subjects: 31
Study 4140268 — intervention group
Group type: COMPARATOR
Intervention: Preoperative controls
Number of subjects: 31
Study 11373164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle (reduced fat and calorie intake and increased activity)
Number of subjects: 23
Study 11373164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle plus ongoing formal evaluation for continuous quality improvement
Number of subjects: 23
Study 11373164 — intervention group
Group type: COMPARATOR
Intervention: Both interventions (intensive lifestyle and intensive lifestyle plus evaluation)
Number of subjects: 23
Study 31310895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostensive labeling events with lexical contrast and/or mutual exclusivity
Number of subjects: 52
Study 31310895 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal linguistic support ('It's a kind of dog.')
Number of subjects: 52
Study 30219433 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina Platensis (4 x 500 mg daily tablets along with restricted calorie diet)
Number of subjects: 52
Study 30219433 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina Platensis
Number of subjects: 52
Study 30219433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo tablets along with restricted calorie diet)
Number of subjects: 52
Study 26886884 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) for urinary incontinence, 12 weekly sessions
Number of subjects: 48
Study 26886884 — intervention group
Group type: COMPARATOR
Intervention: Osteoporosis education (Control)
Number of subjects: 48
Study 26886884 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) for urinary incontinence
Number of subjects: 48
Study 25260723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-mask ventilation
Number of subjects: 196
Study 25260723 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic airway device (SAD)
Number of subjects: 196
Study 25260723 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation
Number of subjects: 196
Study 25260723 — intervention group
Group type: EXPERIMENTAL
Intervention: Further airway interventions
Number of subjects: 196
Study 25260723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation as initial approach
Number of subjects: 196
Study 25260723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-mask as initial approach
Number of subjects: 196
Study 25260723 — intervention group
Group type: EXPERIMENTAL
Intervention: SAD as initial approach
Number of subjects: 196
Study 25260723 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for changing from bag-mask
Number of subjects: 196
Study 25260723 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for removing a SAD
Number of subjects: 196
Study 23094941 — intervention group
Group type: EXPERIMENTAL
Intervention: RealFX™ Q‐Plus™ Chews (500 mg quercetin)
Number of subjects: 18
Study 23094941 — intervention group
Group type: EXPERIMENTAL
Intervention: First Strike™ Bars (500 mg quercetin)
Number of subjects: 18
Study 23094941 — intervention group
Group type: EXPERIMENTAL
Intervention: Tang(®) suspension (500 mg quercetin)
Number of subjects: 18
Study 21180009 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0
Number of subjects: 192
Study 21180009 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II
Number of subjects: 192
Study 21180009 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX U100
Number of subjects: 192
Study 21180009 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem
Number of subjects: 192
Study 21180009 — intervention group
Group type: COMPARATOR
Intervention: 96% isopropanol cleaning
Number of subjects: 192
Study 21180009 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica coating and silanization
Number of subjects: 192
Study 17416908 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of laryngeal tube in anaesthetized state (Group A: 2% sevoflurane)
Number of subjects: 70
Study 17416908 — intervention group
Group type: COMPARATOR
Intervention: Removal of laryngeal tube in awake state (Group B)
Number of subjects: 70
Study 16329364 — intervention group
Group type: EXPERIMENTAL
Intervention: Collamer IOL
Number of subjects: 122
Study 16329364 — intervention group
Group type: COMPARATOR
Intervention: AcrySof IOL
Number of subjects: 122
Study 16329364 — intervention group
Group type: COMPARATOR
Intervention: Plate haptic silicone IOL
Number of subjects: 122
Study 16329364 — intervention group
Group type: COMPARATOR
Intervention: Sensar IOL
Number of subjects: 122
Study 12485286 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 226
Study 12485286 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% and timolol 0.5% fixed combination twice daily
Number of subjects: 226
Study 9807532 — intervention group
Group type: EXPERIMENTAL
Intervention: Community organization approach to promote nonsmoking
Number of subjects: 0
Study 9807532 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated neighborhoods in Kansas City)
Number of subjects: 0
Study 7550011 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Public Speaking (SPS)
Number of subjects: 524
Study 7550011 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroop Color Word Test (SCWT)
Number of subjects: 524
Study 2479177 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection (including total gastrectomy in 64 patients)
Number of subjects: 503
Study 2479177 — intervention group
Group type: COMPARATOR
Intervention: Nonresectional treatment (including bypass and exploratory laparotomy)
Number of subjects: 503
Study 2479177 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection
Number of subjects: 503
Study 2479177 — intervention group
Group type: COMPARATOR
Intervention: Nonresectional procedure
Number of subjects: 503
Study 1190701 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmic acid
Number of subjects: 123
Study 1190701 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone acetate
Number of subjects: 123
Study 1190701 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone acetate
Number of subjects: 123
Study 30317548 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20,000 IU weekly)
Number of subjects: 71
Study 30317548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 27921860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 33
Study 27921860 — intervention group
Group type: COMPARATOR
Intervention: Control (historical group)
Number of subjects: 33
Study 25766269 — intervention group
Group type: EXPERIMENTAL
Intervention: CaCBT plus Treatment As Usual (TAU)
Number of subjects: 137
Study 25766269 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 137
Study 24320193 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care combined with telecare
Number of subjects: 95
Study 24320193 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 95
Study 22634448 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV co-administered with DTPw-HBV/Hib
Number of subjects: 360
Study 22634448 — intervention group
Group type: COMPARATOR
Intervention: Hib vaccine co-administered with DTPw-HBV (Control)
Number of subjects: 360
Study 19579592 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta‐1a
Number of subjects: 21
Study 19579592 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐beta‐1a plus ribavirin (RBV)
Number of subjects: 21
Study 19579592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy or normal ALT on 48w
Number of subjects: 21
Study 19579592 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment biopsies
Number of subjects: 21
Study 19579592 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI, alpha‐SMA, collagen type III values
Number of subjects: 21
Study 17578385 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine treatment
Number of subjects: 0
Study 15126574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD, 120 mg per os)
Number of subjects: 6
Study 15126574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZ, 100 mg per os)
Number of subjects: 6
Study 12092646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenously)
Number of subjects: 64
Study 12092646 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg intramuscularly)
Number of subjects: 64
Study 10322874 — intervention group
Group type: EXPERIMENTAL
Intervention: Qumotang (QMT)
Number of subjects: 214
Study 10322874 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 214
Study 8134155 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 and 5.0 mg prednisolone
Number of subjects: 25
Study 8134155 — intervention group
Group type: COMPARATOR
Intervention: 200 and 800 micrograms inhaled budesonide
Number of subjects: 25
Study 3298294 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures (not specified)
Number of subjects: 0
Study 29868821 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanilla odor (food-associated)
Number of subjects: 150
Study 29868821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose odor (not food-associated)
Number of subjects: 150
Study 29868821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no odor)
Number of subjects: 150
Study 28407162 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac preoperatively
Number of subjects: 42
Study 28407162 — intervention group
Group type: COMPARATOR
Intervention: Control (no NSAID pretreatment)
Number of subjects: 42
Study 28407162 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac
Number of subjects: 42
Study 26204202 — intervention group
Group type: EXPERIMENTAL
Intervention: 555 MBq (15 mCi) of I
Number of subjects: 91
Study 26204202 — intervention group
Group type: EXPERIMENTAL
Intervention: 1110 MBq (30 mCi) of I
Number of subjects: 91
Study 26204202 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses greater than 300 Gy
Number of subjects: 91
Study 26204202 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses less than 300 Gy
Number of subjects: 91
Study 24116747 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler monitor group (51 patients)
Number of subjects: 102
Study 24116747 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 patients)
Number of subjects: 102
Study 20854699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified soya milk
Number of subjects: 12
Study 20854699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented and fortified soya milk
Number of subjects: 12
Study 19058685 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (Kuraray, PF) with method M
Number of subjects: 44
Study 19058685 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (Kuraray, PF) with method NO‐M
Number of subjects: 44
Study 19058685 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiCore Flow (Ivoclar Vivadent, MF) with method M
Number of subjects: 44
Study 19058685 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiCore Flow (Ivoclar Vivadent, MF) with method NO‐M
Number of subjects: 44
Study 19058685 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (Kuraray, PF) with method M (GC)
Number of subjects: 44
Study 19058685 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 (Kuraray, PF) with method NO‐M (GC)
Number of subjects: 44
Study 19058685 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiCore Flow (Ivoclar Vivadent, MF) with method M (GC)
Number of subjects: 44
Study 19058685 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiCore Flow (Ivoclar Vivadent, MF) with method NO‐M (GC)
Number of subjects: 44
Study 16832078 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 0
Study 16832078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12716320 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hysterectomy
Number of subjects: 36
Study 11064385 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT)
Number of subjects: 218
Study 11064385 — intervention group
Group type: COMPARATOR
Intervention: Combined RT and chemotherapy (5-FU plus levamisole)
Number of subjects: 218
Study 9057069 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (first dose 2-4 hours after starting thrombolysis, increased up to 25 mg every 8 hours)
Number of subjects: 45
Study 9057069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9057069 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 45
Study 8314468 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (5 million units, three times weekly)
Number of subjects: 25
Study 8314468 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 25
Study 3470319 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice containing 1% zinc citrate and 0.5% Triclosan
Number of subjects: 0
Study 3470319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29653636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (titrated to 97/103 mg by mouth twice daily for 8 weeks, followed by open-label treatment for 4 weeks)
Number of subjects: 882
Study 29653636 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (titrated to 10 mg by mouth twice daily for 8 weeks)
Number of subjects: 882
Study 29653636 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 882
Study 29653636 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 882
Study 27196650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing a short paper survey with a prepaid incentive ($2 coin)
Number of subjects: 8000
Study 27196650 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey mode (paper vs online)
Number of subjects: 8000
Study 27196650 — intervention group
Group type: COMPARATOR
Intervention: Sampling frame (InfoCanada vs Canada Post)
Number of subjects: 8000
Study 27196650 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire length (10 minutes vs 30 minutes)
Number of subjects: 8000
Study 27196650 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepaid incentive ($2 coin vs none)
Number of subjects: 8000
Study 27196650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery incentive (instant vs end‐of‐study)
Number of subjects: 8000
Study 24238783 — intervention group
Group type: EXPERIMENTAL
Intervention: Go/NoGo task with event-related potentials (ERPs)
Number of subjects: 89
Study 22074724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glulisine insulin using a paper-based glucose-lowering algorithm followed by once-daily subcutaneous insulin glargine for 30 days
Number of subjects: 287
Study 22074724 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic approaches
Number of subjects: 287
Study 20466334 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-lidocaine-propofol (1 mg/kg dexmedetomidine)
Number of subjects: 60
Study 20466334 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-lidocaine-propofol (2 mg/kg fentanyl)
Number of subjects: 60
Study 18661125 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg BID with digoxin (Lanoxicaps 0.2 mg QD)
Number of subjects: 18
Study 18661125 — intervention group
Group type: COMPARATOR
Intervention: Placebo with digoxin (Lanoxicaps 0.2 mg QD)
Number of subjects: 18
Study 15819504 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 1136
Study 15819504 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin treatment)
Number of subjects: 1136
Study 15819504 — intervention group
Group type: COMPARATOR
Intervention: Overall (Statin vs Control)
Number of subjects: 1136
Study 11331318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive combination chemotherapy without local radiation therapy
Number of subjects: 30
Study 9586908 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF 10 microg/kg daily plus filgrastim 12 microg/kg daily for 6 days
Number of subjects: 62
Study 9586908 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF pretreatment (10 microg/kg daily starting 3 days before filgrastim for a total of 10 days)
Number of subjects: 62
Study 9586908 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim alone
Number of subjects: 62
Study 9586908 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF and filgrastim
Number of subjects: 62
Study 7981925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (30 mg 4 times daily for 5 days)
Number of subjects: 20
Study 7981925 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study 7981925 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac tromethamine and Placebo
Number of subjects: 20
Study 2556540 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking advice provided by nurses during health checks
Number of subjects: 4210
Study 2556540 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-smoking advice)
Number of subjects: 4210
Study 2556540 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at health check after intervention
Number of subjects: 4210
Study 2556540 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cotinine measurement
Number of subjects: 4210
Study 5335460 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaolin-agglutination test (KAT)
Number of subjects: 0
Study 36250 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (76 mg/day)
Number of subjects: 21
Study 36250 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (8.2 mg/day)
Number of subjects: 21
Study 36250 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alpha‐adrenoreceptor blockers with beta‐adrenoreceptor blockade
Number of subjects: 21
Study 36250 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 21
Study 30866672 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide-prevention outreach interventions
Number of subjects: 122873